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ates the financial impact of apixaban introduction by comparing expected 1,2, and 
3 years costs in hypothetical scenarios: with and without apixaban. Italian NVAF 
patient population estimation is based on official apixaban reimbursement criteria, 
applying the characteristics of the trial population to national epidemiologic data. 
Sensitivity analysis is performed on an alternative non-experimental population of 
NVAF patients. Results: Among available NOACs, apixaban is expected to be the 
least expensive at 1,2, and 3 years in an estimated patient population of 364,000 
Italian patients, allowing for savings of over 5 million € by the third year. Results of 
the simulation run on an alternative non-experimental population of NVAF patients 
yields comparable estimates. Exclusive use of apixaban for three years in the identi-
fied population would allow for savings of € 8,832,500, € 14,446,551 and € 27,282,998 
when compared with dabigatran (110 mg), dabigatran (150 mg) and rivaroxaban, 
respectively. ConClusions: The different safety and effectiveness profiles of the 
available NOACs emerging from the adjusted indirect comparison indicate that the 
introduction of apixaban could improve health care expenditure control while main-
taining or increasing therapeutic appropriateness in the Italian NVAF population.
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objeCtives: The National Institute of Health and Care Excellence (NICE) issued 
diagnostic guidance on new generation computed tomography (CT) scanners rec-
ommending them as an option for the first-line imaging of coronary arteries in 
patients with suspected low-risk coronary artery disease (CAD) in whom imaging 
with old generation scanners is difficult (e.g. obese patients). The capital investment 
for a new generation scanner is considerably more than a standard scanner, which 
could hamper implementation. Based on the NICE guidance, a model was designed 
for use as a planning tool for rapid access chest pain clinics (RACPCs) looking to 
replace their current scanner with a new generation scanner. Methods: An Excel® 
model was developed to estimate up to a 10-year impact of acquiring a new genera-
tion scanner. It was assumed that under standard care low-risk, difficult-to-image 
patients would be referred for a diagnostic invasive coronary angiography (ICA). 
Under the new diagnostic pathway these patients can be scanned with a new gener-
ation scanner. Whenever possible the NICE guidance was used to guide assumptions 
and populate default values. Results: The model estimates that for each difficult-
to-image patient a new generation scanner has the potential to save approximately 
£946.62 in diagnostic costs. Considering the capital investment required, a RACPC 
looking to replace their standard scanner and considering implementing a new 
generation CT scanner only need 53 difficult-to-image patients per year to see a 
positive return on investment over a 10-year period. ConClusions: The model is 
likely to be conservative as it focuses on difficult-to-image patients only, yet the 
scanner is available for all patients who will likely benefit from the better sensitivity 
and specificity associated with the new scanners. However, it highlights that even 
a low number of these difficult-to-image patients will result in a positive return on 
investment over the expected life-time of the scanner.
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objeCtives: To evaluate the affordability of switching patients already treated with 
the multi-pill therapy of simvastatin and fenofibrate to the first simvastatin and 
fenofibrate fixed dosed combinations (FDC) product, for the management of mixed 
dyslipidemia in the Greek health care setting. Methods: A budget impact model 
was locally adapted. The analysis was conducted from a third-party payer perspec-
tive over a time horizon of 3 years. The population with mixed dyslipidemia in 
Greece, the market shares of available treatments and the corresponding drug acqui-
sition costs were combined to estimate the total budgetary impact that will result 
from the penetration of FDC in the Greek market. Data on population with mixed 
dyslipidemia were derived from the National Statistical Service and published litera-
ture. Estimates of the current and future market shares were obtained from Abbott 
Hellas market research. Drug acquisition costs were calculated using the latest 
price bulletin issued and the corresponding reimbursement prices. Reimbursement 
prices were reduced by the patient’s relevant co-payment and relative rebates. Since 
market prices for the FDC are not available yet in Greece, estimated retail prices 
provided by Abbott Hellas were considered [FDC 20/145: € 13.70 (€ 12.22-16.27) and 
FDC 40/145: € 16.71 (€ 15.22-19.23)]. Results: Savings in pharmaceutical reimburse-
ment on year 1 were estimated at 146,974 (€ 181,084-€ 88,503) decreasing the relevant 
cost by 5.87% (7.23%-3.53%). On year 2, savings of € 250,544 (€ 322,536-€ 136,474) were 
attributed to the penetration of FDC, lowering the budget by 9.93% (12.78%-5.41%). 
On the 3rdyear, savings were estimated at € 403,405 (€ 509,489-€ 221,565) reducing 
spending by 15.82% (19.98%-8.69%). On average, over the 3-year time horizon of the 
analysis, the addition of FDC was found to decrease reimbursement costs by 10.54% 
(13.33%-5.88%) generating savings of € 266,974 (337,703€ -€ 148,147). ConClusions: 
The introduction of FDC reimbursement will result in a predictable budget impact 
which is expected to decrease the relevant pharmaceutical cost for national health 
insurance.
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objeCtives: Upper limb spasticity (ULS) secondary to stroke has a considerable 
patient and caregiver burden, particularly with regards to pain, activities of daily 
quitting smoking. Cost of 5-year reimbursement varenicline was estimated to 
be € 63.0 millions, while smoking cessation avoided costs reached € 99.9 millions, 
which compared with € 21.1 millions savings in the not-reimbursed scenario: a net 
incremental cost-saving of € 15.9 millions. Savings were observed since 3rd year of 
modelling. ConClusions: The BI of the reimbursement of varenicline in smoking 
cessation is a cost-effective health policy in the Spanish NHS, and could produce 
cost-savings since the 3rd year of implementation.
PCV37
BudgeT ImPaCT aNalySIS Of hyPerTeNSIVe TreaTmeNT wITh INdaPamIde 
aNd amlOdIPINe SINgle-PIll COmBINaTION IN The POlISh SeTTINg
Kawalec P.1, Stawowczyk E.2, Holko P.2, Borowiec L.3, Filipiak K.J.4
1Jagiellonian University Medical College, Krakow, Poland, 2Centrum HTA Sp z o. o. Sp. 
komandytowa, Kraków, Poland, 3Medical Department, Servier Poland Ltd, Warsaw, Poland, 41st 
Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
objeCtives: The aim of this study was to calculate and compare public payer and 
patients’ costs of hypertensive treatment with indapamide 1.5 mg and amlodipine 
5 mg or 10 mg single-pill combination (SPC) and free combination (FC), in the Polish 
setting. Methods: The analysis compared two scenarios: existing and new. The 
existing one assumed treatment with FC of indapamide 1.5 mg and amlodipine 5 
mg or 10 mg. The new one also included treatment with SPC of indapamide 1.5 mg 
+amlodipine 5/10 mg. Population and market shares were estimated on the basis of 
published reimbursement data, experts’ opinion and validated with available epide-
miological data. Cost data were analysed from the public payer perspective (National 
Health Fund) and from patient perspective, in a three-year horizon. SPC cost is based 
on average pharmacy price reported in April 2014 (18.13PLN and 19.75PLN respec-
tively for 1.5+5mg and 1.5+10mg /30 tabs); 30% patient copayment was assumed. 
The cost of FC was calculated as an average cost of reimbursed indapamide and 
amlodipine products in corresponding doses. All costs present 2014 values, and are 
expressed in Polish zloty (PLN). Average monthly exchange rate of May 2014 was 
applied (1EUR= 4.1790PLN). Difference in clinical effectiveness between SPC and FC 
was also included, in the form of cardiovascular events risk. Results: Introduction 
of indapamide/amlodipine SPC on the reimbursement list next to FC brought savings 
from public payer perspective and from patient perspective amounting to: 509,255PLN 
(121,860EUR) and 5,893,941PLN (1,410,371EUR) in first year, 689,239PLN (164,929EUR) 
and 7,833,005PLN (1,874,373EUR) in second year, 725,965PLN (173,717EUR) and 
8,328,480PLN (1,992,936EUR) in third year. Additionally it resulted in avoidance of 
808 cardiovascular events in the three-year horizon. ConClusions: Treatment with 
indapamide/amlodipine SPC in comparison to FC generates significant savings both 
from the public payer perspective and from patient perspective in contemporary 
Polish setting, and reduces cardiovascular events.
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objeCtives: Despite the availability of numerous therapeutic agents and manage-
ment tools, half of all hypertensive patients do not have their blood pressure (BP) 
at goal. A model was developed to estimate the incremental costs of uncontrolled 
vs. controlled hypertension and the impact of shifting patients to controlled sta-
tus via a unique digital health feedback system. This Proteus system utilizes an 
Ingestible Sensor to determine medication-taking patterns, and a wearable 7-day 
sensor in the form of an adhesive patch to collect physiological and behavioral 
metrics such as heart rate, step count, and patterns of activity and rest, providing 
a means of determining non-response vs. non-adherence to prescribed medica-
tions and recommendations for daily routine. Methods: The additional costs of 
outpatient services, monitoring, and cardiovascular complications were calculated 
for uncontrolled vs. controlled hypertensive patients from a US plan perspective for 
a 1 year time horizon. The clinical and utilization assumptions were derived from 
the literature and expert opinion, and costs were derived from the Medicare Fee 
Schedule and AHRQ databases. The impact of the Proteus system on BP control was 
based on a real-world study evaluating this technology in 164 patients with a history 
of uncontrolled hypertension. Results: In a health plan of 1 million members, 7.9% 
(78,656) were uncontrolled hypertensive patients receiving care who were eligible for 
the Proteus system. The direct annual medical costs of uncontrolled hypertension 
were estimated to be $60.9 million over the costs for controlled disease. The Proteus 
system was estimated to result in $7.3-18.3 million in savings ($328-$717 per BP at 
goal), and lead to a 3-9% reduction in the number of coronary artery disease and 
stroke events in one year. ConClusions: Even in the short-term, a digital health 
feedback system appears to provide an effective way to mitigate the substantial 
costs of uncontrolled hypertension.
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objeCtives: This study aims to perform a budget impact analysis of the use of three 
available novel oral anticoagulant agents (NOACs) for preventing thromboembolic 
events in Italian patients with non-valvular atrial fibrillation (NVAF). Methods: 
Estimated Italian population of patients is run through a decision tree/Markov 
model simulating their treatment with the available therapeutic options: dabigatran 
at two dose levels (110 mg/bid for the over 80 years old, 150 mg/bid for younger NVAF 
patients), rivaroxaban, and apixaban. Effectiveness estimates derive from an adjusted 
indirect treatment comparison using warfarin as link. Epidemiological data and unit 
costs are collected from Italian published sources. The budget impact analysis evalu-
